Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers identify drugs with fewest side-effects for treating irritable bowel syndrome

26.03.2012
Cedars-Sinai researchers have determined that two prevalent drug therapies – rifaximin and lubiprostone – offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

The findings, based on an analysis of more than two dozen large-scale clinical trials, are contained in a peer-reviewed study published online by The American Journal of Medicine and set to appear in the publication’s April print edition.

Patients with irritable bowel syndrome often experience abdominal pain or cramps, excess gas or bloating and visible abdominal distension. Many drug therapies cause troubling side effects of their own, including nausea, insomnia, palpitations and decreased appetite.

“For the millions of patients who suffer from IBS, effective treatment options have been very scarce,” said Dr. Mark Pimentel, a lead author of the study and director of Cedars-Sinai’s Gastrointestinal Motility Program.

Pimentel and the other researchers analyzed common treatments for IBS.

For diarrhea forms of the condition, they evaluated tricyclic antidepressants; alosetron, a drug that slows movement of stool in the gut; and rifaximin, an antibiotic that stays in the gut and is currently FDA-approved to treat traveler’s diarrhea and hepatic encephalopathy.

For constipation forms of IBS, the researchers examined antidepressants known as serotonin reuptake inhibitors and lubiprostone, a drug that promotes gut secretion.

The research found striking differences:

• For every 2.3 patients who benefited from tricyclic antidepressants, one suffered harmful side effects and had to stop taking the medication.

• For every 2.6 patients helped by alosetron, one had to halt the drug.

• By contrast, for every 846 patients aided by rifaximin, one had to discontinue the medication.

• Lubiprostone and serotonin reuptake inhibitors demonstrated a complete lack of “harm” to IBS patients with constipation, as defined by the study.

“We found that rifaximin and lubiprostone have the lowest level of harmful side effects of all the well-studied drug therapies for IBS,” Pimentel said.

“This underscores the need for us to continue to monitor new therapies for this disease,” Pimentel added. “While it is important to see benefit with drugs, harm is something we do not often assess well."

Besides Cedars-Sinai, other centers participating in the research included the School of Medicine at Texas Tech University’s Health Sciences Center; the UCLA Department of Medicine; Beth Israel Deaconess Medical Center; and Harvard Medical School.

Funding for the study was provided by the Beatrice and Samuel A. Seaver Foundation.

Pimentel discovered the use of rifaximin for IBS. Cedars-Sinai holds patent rights to the discovery and has a licensing agreement with Salix Pharmaceuticals Inc., which markets the drug. Pimentel is a consultant to Salix and serves on its scientific advisory board. None of the authors is affiliated with lubiprostone maker Takeda Pharmaceuticals or other drugs that were evaluated.

Duke Helfand | Cedars-Sinai News
Further information:
http://www.cshs.org

More articles from Life Sciences:

nachricht A new view of microscopic interactions
01.07.2020 | University of Missouri-Columbia

nachricht Microscope allows gentle, continuous imaging of light-sensitive corals
01.07.2020 | Marine Biological Laboratory

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: ILA Goes Digital – Automation & Production Technology for Adaptable Aircraft Production

Live event – July 1, 2020 - 11:00 to 11:45 (CET)
"Automation in Aerospace Industry @ Fraunhofer IFAM"

The Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM l Stade is presenting its forward-looking R&D portfolio for the first time at...

Im Focus: AI monitoring of laser welding processes - X-ray vision and eavesdropping ensure quality

With an X-ray experiment at the European Synchrotron ESRF in Grenoble (France), Empa researchers were able to demonstrate how well their real-time acoustic monitoring of laser weld seams works. With almost 90 percent reliability, they detected the formation of unwanted pores that impair the quality of weld seams. Thanks to a special evaluation method based on artificial intelligence (AI), the detection process is completed in just 70 milliseconds.

Laser welding is a process suitable for joining metals and thermoplastics. It has become particularly well established in highly automated production, for...

Im Focus: A structural light switch for magnetism

A research team from the Max Planck Institute for the Structure of Dynamics (MPSD) and the University of Oxford has managed to drive a prototypical antiferromagnet into a new magnetic state using terahertz frequency light. Their groundbreaking method produced an effect orders of magnitude larger than previously achieved, and on ultrafast time scales. The team’s work has just been published in Nature Physics.

Magnetic materials have been a mainstay in computing technology due to their ability to permanently store information in their magnetic state. Current...

Im Focus: Virtually Captured

Biomechanical analyses and computer simulations reveal the Venus flytrap snapping mechanisms

The Venus flytrap (Dionaea muscipula) takes only 100 milliseconds to trap its prey. Once their leaves, which have been transformed into snap traps, have...

Im Focus: NASA observes large Saharan dust plume over Atlantic ocean

NASA-NOAA's Suomi NPP satellite observed a huge Saharan dust plume streaming over the North Atlantic Ocean, beginning on June 13. Satellite data showed the dust had spread over 2,000 miles.

At NASA's Goddard Space Flight Center in Greenbelt, Maryland, Colin Seftor, an atmospheric scientist, created an animation of the dust and aerosols from the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

First exposed planetary core discovered

01.07.2020 | Physics and Astronomy

Energy-saving servers: Data storage 2.0

01.07.2020 | Power and Electrical Engineering

Laser takes pictures of electrons in crystals

01.07.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>